350: A multicenter, randomized, double-blind, placebo-controlled phase 2 trial of retosiban, a selective oxytocin receptor antagonist, for the management of preterm labor - 28/12/12
Doi : 10.1016/j.ajog.2012.10.515
Jerry Snidow 1, Hugh Miller 2, Guillermo Valenzuela 3, Steve Thornton 4, Brendt Stier 5, Linda Clayton 6, Mike Fossler 7, Tim Montague 8, Kathleen Beach 9, Pauline Williams 10
1 GlaxoSmithKline, Metabolic Pathways and Cardiovascular Therapeutic Area, RTP, NC
2 Watching Over Mothers and Babies, Obstetrics, Tucson, AZ
3 Arrowhead Regional Medical Center, Obstetrics, Colton, CA
4 University of Exeter Medical School, Medicine, Exeter, United Kingdom
5 GlaxoSmithKline, Clinical Pharmacology Science and Study Operations, King of Prussia, PA
6 GlaxoSmithKline, Global Clinical Safety and Pharmacovigilance, RTP, NC
7 GlaxoSmithKline, Clinical Pharmacology Modelling and Simulation, King of Prussia, PA
8 GlaxoSmithKline, Drug Discovery Biostatistics, King of Prussia, PA
9 GlaxoSmithKline, Alternative Discovery and Development, RTP, NC
10 GlaxoSmithKline, Academic Discovery Performance Unit, Stevenage, United Kingdom
Le texte complet de cet article est disponible en PDF.
Plan
© 2013
Mosby, Inc. Tous droits réservés.
Vol 208 - N° 1S
P. S155 - janvier 2013 Retour au numéro
Article précédent
- 349: Weight loss in overweight and obese pregnant women (OW/OB): what is the effect on fetal growth?
- Patrick Catalano
- 351: Identification of cervical-vaginal biomarkers of recurrent preterm birth by proteomic analysis
- Leonardo Pereira, Ashok Reddy, Phillip Wilmarth, Amanda Kinhnarath, Janice Snyder, Monica Rincon, Jodi Lapidus, Mallika Yavatkar, Michael Gravett, Srinivasa Nagalla
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?